A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GZR4 in Subjects With Type 2 Diabetes

Inclusion Criteria:

• Male or female at the age of 18-65 (inclusive) at the time of informed consent

• Body mass index (BMI) between 18.5 and 35 kg/m2 (inclusive) at screening

• Diagnosis of type 2 diabetes mellitus for over 3 months

• Hemoglobin A1c (HbA1c) ≥ 6.5% and ≤ 10.0% at screening.

Exclusion Criteria:

• History of drug abuse within 1 year before screening, or positive drug abusescreening results during the screening period or at baseline

• Malignancy or increased risk of malignancy before screening: any suspected and/ordiagnosed malignancy or documented history of malignancy

• Confirmed or suspected type 1 diabetes mellitus, gestational diabetes mellitus, orspecific types of diabetes mellitus from other causes (monogenic diabetes syndrome,cystic fibrosis, pancreatitis, drug-induced or chemically induced diabetes mellitus,etc.) prior to screening

• Presence of the following diseases within 6 months prior to screening: diabeticketoacidosis, diabetic lactic acidosis, or hyperosmolar nonketotic diabetic coma;proliferative retinopathy or maculopathy that is unstable or requiring treatment;symptomatic diabetic neuropathy, intermittent claudication or diabetic foot

• Severe hypoglycaemic events (Level 3 hypoglycaemia) within 6 months prior toscreening, or 3 or more hypoglycaemic events (blood glucose ≤ 3.9 mmol/L) within 1month prior to screening, or recurrent hypoglycaemia-related symptoms